Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03180593 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH
A Phase 4 study of Blood Pressure and Hypertension Complicated, sponsored by Trinity Hypertension & Metabolic Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03180593: Completed Phase 4 study of Blood Pressure and Hypertension Complicated, sponsored by Trinity Hypertension & Metabolic Research Institute.
NCT03180593 is a Phase 4 study of Blood Pressure and Hypertension Complicated that has completed, run by Trinity Hypertension & Metabolic Research Institute. The registered enrollment target is 30 participants, below the 287-participant average among 101 other Blood Pressure trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03180593, a Phase 4 study of Blood Pressure and Hypertension Complicated, has completed, sponsored by Trinity Hypertension & Metabolic Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the efficacy of Left Ventricular Hypertrophy (LVH) reduction and 24-hour blood pressure control of Valsartan 80mg or Nebivolol/Valsartan 5/80mg once daily as replacement therapy for currently treated or untreated hypertensive patients with LVH not at BP goal.
Primary Outcome
Reduction of Left ventricular hypertrophy from baseline compared to 4 weeks of treatment
Conditions Studied
Interventions
- DRUG Valsartan 80 mg
Study Locations (1)
Texas
- Trinity Hypertension & Metabolic Research Institute - Carrollton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-02-07 |
| Est. Completion | 2018-01-25 |
| Phase | Phase 4 |
What the finished NCT03180593 record still lists
NCT03180593 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 287-participant average among 101 other Blood Pressure trials with a reported enrollment target (90% lower).
The record links to 3 conditions, with Blood Pressure appearing as the primary indexed condition, and to 1 intervention - of which Valsartan 80 mg is the first listed.
NCT03180593 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03180593 about?
NCT03180593 is a clinical study titled "Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH". To assess the efficacy of Left Ventricular Hypertrophy (LVH) reduction and 24-hour blood pressure control of Valsartan 80mg or Nebivolol/Valsartan 5/80mg once daily as replacement therapy for currently treated or untreated hypertensive patients with LVH not at BP goal.
What is the current status of trial NCT03180593?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2017-02-07. Estimated completion is 2018-01-25.
What conditions does trial NCT03180593 study?
This clinical trial studies the following conditions: Blood Pressure, Hypertension Complicated, Hypertrophy, Left Ventricular.
What interventions are being tested in trial NCT03180593?
The interventions under investigation include: Valsartan 80 mg (DRUG).
Who is sponsoring clinical trial NCT03180593?
This trial is sponsored by Trinity Hypertension & Metabolic Research Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03180593 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blood Pressure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03180593's enrollment target sits among peer trials
30 76th of 101 higher than 21 of 101 other Blood Pressure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Blood Pressure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans
ACTIVE NOT RECRUITING · Phase 4
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
RECRUITING
-
Autonomic Regulation of Blood Pressure in Premature and Early Menopausal Women
RECRUITING
-
Cocooned Moms Study
RECRUITING · NA
-
VicorderCS NIBP Validation Study to Review The Ability to Capture Blood Pressure Measurements
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI